Sarepta Therapeutics (NASDAQ:SRPT) Coverage Initiated by Analysts at Jefferies Financial Group

Jefferies Financial Group began coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report sent to investors on Monday, Marketbeat reports. The firm issued a buy rating and a $165.00 target price on the biotechnology company’s stock.

Other equities research analysts also recently issued reports about the company. Raymond James reaffirmed an “outperform” rating and set a $150.00 target price on shares of Sarepta Therapeutics in a report on Thursday, October 10th. BMO Capital Markets raised their price objective on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the stock an “outperform” rating in a research note on Monday, June 24th. Needham & Company LLC reissued a “buy” rating and set a $205.00 target price on shares of Sarepta Therapeutics in a research note on Monday, October 14th. Barclays decreased their target price on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Finally, Evercore ISI raised Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and dropped their price target for the company from $185.00 to $179.00 in a research report on Thursday, August 8th. Two analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $182.95.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT opened at $127.31 on Monday. The firm has a 50-day moving average of $129.00 and a two-hundred day moving average of $132.39. The company has a market capitalization of $12.03 billion, a price-to-earnings ratio of 1,157.36 and a beta of 0.82. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05. Sarepta Therapeutics has a twelve month low of $55.25 and a twelve month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The business had revenue of $362.90 million during the quarter, compared to analyst estimates of $394.38 million. During the same period in the prior year, the business earned ($0.27) earnings per share. The business’s quarterly revenue was up 38.9% on a year-over-year basis. As a group, analysts expect that Sarepta Therapeutics will post 1.45 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Michael Andrew Chambers purchased 37,038 shares of the firm’s stock in a transaction on Friday, August 16th. The shares were purchased at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the acquisition, the director now directly owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 7.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Capital International Investors grew its stake in shares of Sarepta Therapeutics by 1.6% in the first quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company’s stock worth $623,676,000 after acquiring an additional 76,032 shares during the last quarter. Farallon Capital Management LLC grew its position in Sarepta Therapeutics by 102.8% in the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after purchasing an additional 1,243,427 shares during the last quarter. Thrivent Financial for Lutherans grew its position in Sarepta Therapeutics by 6.3% in the 2nd quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company’s stock worth $101,858,000 after purchasing an additional 37,940 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in shares of Sarepta Therapeutics by 26.3% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 579,637 shares of the biotechnology company’s stock worth $75,040,000 after purchasing an additional 120,535 shares during the period. Finally, Fiera Capital Corp raised its position in shares of Sarepta Therapeutics by 4.3% during the second quarter. Fiera Capital Corp now owns 382,645 shares of the biotechnology company’s stock valued at $60,458,000 after buying an additional 15,606 shares during the last quarter. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.